01 — Identity

Name & Classification

BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in human gastric juice — specifically a partial sequence of Body Protection Compound, an endogenous protein produced in the stomach.

Its chemical designation is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is classified as a cytoprotective and regenerative peptide with systemic healing effects spanning musculoskeletal tissue, gut, CNS, and vascular endothelium.

One of the most extensively researched peptides in animal models, with over 100 published studies demonstrating remarkable healing and protective properties across multiple organ systems.

02 — Origin

When It Was Developed

1993

BPC-157 first described by Dr. Predrag Sikiric and colleagues at the University of Zagreb, Croatia. Isolated from human gastric juice protein as part of research into gastrointestinal cytoprotection.

1990s–2000s

Prolific animal research from the Zagreb group demonstrated healing across an extraordinary range of tissues: tendons, ligaments, muscles, bone, gut mucosa, peripheral nerves, and brain. Published in peer-reviewed journals.

2000s

Mechanism research revealed BPC-157 upregulates growth hormone receptors, stimulates VEGF-mediated angiogenesis, modulates nitric oxide, and activates FAK-paxillin signaling in tendon fibroblasts.

2010s

Widespread adoption in sports medicine and injury recovery. Neuroprotective properties studied in TBI and addiction models. FDA granted orphan drug status consideration for IBD-related indications.

2022–Present

One of the most popular research peptides globally. FDA removed BPC-157 from bulk compounding list in 2022 — availability through compounding pharmacies restricted in the US; remains available as research chemical.

03 — Research History

Research Background

BPC-157 has the deepest animal research base of any peptide in the wellness space — with studies demonstrating healing effects on virtually every tissue type examined. Its healing mechanisms are multifactorial: it upregulates growth hormone receptor expression (making the body more responsive to its own GH), stimulates VEGF to grow new blood vessels into damaged tissue, and activates the FAK-paxillin pathway in fibroblasts to accelerate tendon and ligament repair.

Gastrointestinal effects are particularly robust — BPC-157 heals gastric ulcers, protects against NSAID-induced gut damage, repairs intestinal fistulas, and reverses short bowel syndrome in rat models. It is believed to be part of the stomach's endogenous self-repair system.

Neurological effects have become a major area of research: BPC-157 accelerates recovery from traumatic brain injury, protects against neurotoxins, modulates dopamine and serotonin systems (showing promise in addiction and mood dysregulation models), and reverses drug-induced movement disorders in rats. No human clinical trials have been completed and published to date.

04 — Key Benefits

Proposed Benefits

Accelerates tendon, ligament, and muscle repair

Heals gastric ulcers and protects gut mucosa

Stimulates angiogenesis (VEGF) in damaged tissue

Upregulates growth hormone receptor expression

Accelerates bone healing and fracture repair

Neuroprotective — TBI recovery and nerve regeneration

Modulates dopamine/serotonin — addiction and mood support

Anti-inflammatory via NF-κB and nitric oxide pathways

Protects against NSAID and alcohol-induced GI damage

Oral bioavailability for gut-targeted protocols

05 — Reconstitution

10 mg Vial + 300 Units BAC Water

33.3 mcg

per unit drawn on insulin syringe

10,000

mcg total

0.3 mL

total volume

4–6 wk

shelf life (fridge)

🧊

RECONSTITUTED SHELF LIFE

30 days after mixing

One of the most stable peptides post-reconstitution. Still cap at 30d for potency.

            Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze

            Preload syringes/cartridges to minimize vial disturbance

BPC-157 is also available in oral capsule form (typically 250–500 mcg) for gut-focused protocols. Injectable is preferred for systemic and musculoskeletal applications. Some practitioners inject locally near the injury site for concentrated healing effect. Store refrigerated; do not freeze reconstituted vial.

06 — Dosage

Dosage Reference

Dose	Units to Draw	Context
200–250 mcg SC	6–7.5 u	LOW / INTRO
500 mcg SC	15 u	COMMON
500 mcg–1 mg oral	1–2 capsules	GUT PROTOCOL
1,000 mcg (1 mg) SC	30 u	STANDARD
10 mcg/kg (research)	weight-based	ANIMAL EQUIVALENT

Most protocols use 250–500 mcg once or twice daily. For injury recovery, some practitioners inject subcutaneously near the injury site (not directly into tendons). For gut conditions, oral is preferred. Once-daily dosing is most common; twice-daily for acute injury. BPC-157 has an exceptional safety profile in all animal studies with no identified LD50.

07 — Monitoring

Biomarkers, Lab Tests & Ranges

BPC-157 acts across multiple systems. Key monitoring targets connective tissue healing, gut health, inflammation, and angiogenic activity.

▸ Tissue Repair & Healing

Biomarker	Lab Test	Clinical Range	Optimal Range
IGF-1 Tissue repair growth factor	Serum IGF-1	CLINICAL~115–355 ng/mL (adult)	OPTIMALUpper 1/3 of age range
VEGF Vascular endothelial growth factor	Serum VEGF	CLINICAL62–707 pg/mL	OPTIMALTrending up from baseline during healing phase
COMP Cartilage / tendon matrix marker	Serum COMP	CLINICAL<12 U/L	OPTIMAL<8 U/L (stable/declining)

▸ Gut Health

Biomarker	Lab Test	Clinical Range	Optimal Range
Calprotectin	Stool Calprotectin	CLINICAL<50 µg/g	OPTIMAL<25 µg/g
Zonulin	Serum or Stool Zonulin	CLINICAL<107 ng/mL	OPTIMAL<40 ng/mL

▸ Inflammation & Safety

Biomarker	Lab Test	Clinical Range	Optimal Range
hsCRP	High-sensitivity CRP	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L
IL-6	Serum IL-6	CLINICAL<7.0 pg/mL	OPTIMAL<1.5 pg/mL
AST / ALT	CMP	CLINICALAST 10–40 / ALT 7–56 U/L	OPTIMALAST <26 / ALT <26 U/L
CBC	Complete Blood Count	CLINICALStandard ranges	OPTIMALMid-range; WBC 4.5–6.0

READY TO ADD THIS TO YOUR STACK?

Drop BPC-157 into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Returns you here after.

⚠ BPC-157 has no completed human clinical trials. Animal data is extensive and uniformly positive. No LD50 has been established — it is considered among the safest research peptides. FDA removed it from US compounding lists in 2022; source from reputable research suppliers and consult a practitioner.

08 — Cycle Protocol

Cycle Length, Frequency & Timing

▸ How Long to Cycle

INJURY RECOVERY

4–8 Weeks

For acute injury recovery, 4–8 week cycles are typical — aligned with tissue healing timelines. Many users report significant improvement within 2–4 weeks.

GUT / CHRONIC USE

12–16 Weeks

For IBD, leaky gut, or systemic anti-inflammatory use, longer 12–16 week cycles are common with a 4–8 week break before re-cycling if needed.

BPC-157 has no established receptor desensitization or tolerance in the literature. Its extraordinary safety profile means longer cycles are not considered high-risk. However, cycling with breaks allows proper biomarker re-assessment and is considered best practice.

▸ Frequency & Timing

Variable	Recommendation	Why
Frequency	Daily or twice daily	Once daily is standard for maintenance and gut healing. Twice daily (AM + PM) used for acute injuries to maintain consistent healing signal throughout the day.
Fasted (injectable)	✓ Preferred but flexible	AM fasted injection is conventional and most common. BPC-157 absorption is not strongly food-dependent but fasted state minimizes competition with digestive processes.
Oral (gut protocol)	✓ With food or fasted	For GI conditions, taking orally on an empty stomach may improve direct mucosal contact. Some prefer with food for tolerability — both approaches are used in practice.
Local injection	✓ Near injury site (SC)	For tendon/ligament injuries, injecting subcutaneously near (not into) the injury site is a common approach to concentrate healing activity. Do not inject into tendons directly.
Timing	AM preferred	Morning dosing is most common. For twice-daily, AM and PM split is standard. No strong circadian timing dependency has been identified in BPC-157 research.

PROTOCOL SUMMARY

4–16 wk

CYCLE (use case)

1–2×

DAILY

AM

TIMING

SC or Oral

ROUTE

4–8 wk

BREAK